Cargando…
1298. High Prescription Rate of Medications with Significant Rifampin Drug Interactions in Patients with Diabetic Foot Osteomyelitis: Should Rifabutin be Included in Clinical Trials for Adjunctive Therapy?
BACKGROUND: Diabetic foot osteomyelitis (DFO) is a leading cause of amputations. Rifamycins can penetrate osteoblasts and disrupt biofilm, making them ideal adjunctive antibiotics for DFO. A recent retrospective DFO study found that rifampin adjuvant therapy was associated with significantly higher...
Autores principales: | Mallarino-Haeger, Christina, Watson, Allison, Mahgoub, Umnia, Francis, Lily, Heydari, Maryam, Choudhary, Muaaz, Kempker, Russell R, Schechter, Marcos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677499/ http://dx.doi.org/10.1093/ofid/ofad500.1137 |
Ejemplares similares
-
Adjunctive Rifampin Therapy For Diabetic Foot Osteomyelitis in the Veterans Health Administration
por: Wilson, Brigid M., et al.
Publicado: (2019) -
Ex Vivo Human Placental Transfer of Rifampin and Rifabutin
por: Magee, Kevin P., et al.
Publicado: (1996) -
Successful Anticoagulation With Warfarin After Switching From Rifampin to Rifabutin
por: Alnewais, Marwah E., et al.
Publicado: (2023) -
rpoB Mutations are Associated with Variable Levels of Rifampin and Rifabutin Resistance in Mycobacterium tuberculosis
por: Li, Ma-Chao, et al.
Publicado: (2022) -
In Vitro Activity of Rifampin, Rifabutin, and Rifapentine against Enterococci and Streptococci from Periprosthetic Joint Infection
por: Albano, Mariana, et al.
Publicado: (2021)